ライフサイエンスコーパス: antibody response

1 , mild SARS-CoV-2 infections induce a modest antibody response.

2 fate dynamics and thus, the character of the antibody response.

3 oconvert and mount an antiviral neutralizing antibody response.

4 ent the elicitation of a specific SARS-CoV-2 antibody response.

5 ose binding proteins, which could affect the antibody response.

6 rategies to avoid neutralization by the host antibody response.

7 the breadth and effectiveness of the ensuing antibody response.

8 pid (CoPoP) potently enhances the functional antibody response.

9 ell responses correlated with spike-specific antibody responses.

10 T-cell but not immunoglobulin (Ig) M or IgG antibody responses.

11 ther with diminished T cell-independent (TI) antibody responses.

12 rminal center activity and enhance HIV-1 Env antibody responses.

13 nd comparable peak gB-binding and functional antibody responses.

14 T-cell and ZIKV-specific serum-neutralizing antibody responses.

15 ost genetic and non-genetic factors on virus antibody responses.

16 blunted CD4 T-cell responses and diminished antibody responses.

17 l and systemic T-dependent and T-independent antibody responses.

18 prior infections that produce cross-reactive antibody responses.

19 ially hinder induction of broad neutralizing antibody responses.

20 system in addition to induction of specific antibody responses.

21 lted in the generation of serum-neutralizing antibody responses.

22 y profile, and homologous boosting increased antibody responses.

23 of all vaccines work by inducing protective antibody responses.

24 on the magnitude and characteristics of the antibody responses.

25 a high likelihood of having strong antiviral antibody responses.

26 e durability and breadth of vaccine-elicited antibody responses.

27 en correlated with evasion from neutralizing antibody responses.

28 neutralization exhibited similar patterns in antibody responses.

29 antly, became more sensitive to neutralizing antibody responses.

30 of 209 boosted participants had neutralising antibody responses.

31 efficiently and induced significantly higher antibody responses.

32 d the cationic emulsions induced the highest antibody responses.

33 nal manner for induction of antigen-specific antibody responses.

34 e fur and diminished T cell-independent (TI) antibody responses.

35 poxia response mechanisms and T cell help to antibody responses.

36 s, viral shedding in body fluids, and vector antibody responses.

37 d an enhanced durability of vaccine-elicited antibody responses.

38 seroconverters make detectable neutralizing antibody responses.

39 IV-1 vaccine-induced antienvelope (anti-Env) antibody responses.

40 otein antigens for induction of neutralizing antibody responses.

41 f polyreactivity during anti-influenza virus antibody responses.

42 ological memory in the dynamics of HA and NA antibody responses.

43 ccination requires elicitation of long-lived antibody responses.

44 Based on these data, a neutralizing antibody response above 3.02 log(10) EC50 was determined

45 for COVID-19 were associated with increased antibody responses across the serological assays.

46 veloped neutralization assays to investigate antibody responses, adapted our high-throughput antibody

47 ze different aspects of the anti-mumps virus antibody response after vaccination.

48 from infected patients, and readily induced antibody responses after vaccination of mice.

49 reveal the antibody response against all ebolavirus proteins by ana

50 e molecular basis for the neutralizing human antibody response against EEEV and can facilitate develo

51 nanoparticles to the spleen led to improved antibody response against the antigen, higher central me

52 to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP

53 esses underlying influenza infection and our antibody response against the virus have been thoroughly

54 gher prevalence and diversity of HA-specific antibody responses against 11 different subtypes.

55 ix-M-adjuvanted qNIV induced superior wt-HAI antibody responses against 5 of 6 homologous or drifted

56 TAK-003 elicited antibody responses against all four serotypes, which per

57 or intradermally, eliciting serum and fecal antibody responses against CfaE and LTB, as well as stro

58 times during the vaccination phase to assess antibody responses against CHIKV.

59 with SOSIP-NVP elicited strong neutralizing antibody responses against HIV-1.

60 c anti-DSG3 IgG levels, DSG3-CAART inhibited antibody responses against pathogenic DSG3 epitopes and

61 with RBD-NVP induced robust and long-lasting antibody responses against RBD from SARS-CoV-2.

62 immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice.

63 Neutralising antibody responses against SARS-CoV-2 were detected in 3

64 onsidered for inducing strongly neutralizing antibody responses against SARS-CoV-2.

65 cine did not provide sufficient heterologous antibody responses against the new 2010.1 cluster A(H3N2

66 COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein.

67 Reinfections can boost antibody responses against viral strains first encounter

68 There was substantial heterogeneity in the antibody response among potential convalescent plasma do

69 genic sites, which may elicit a more diverse antibody response and broader protection against infecti

70 Correcting for cases without a detectable antibody response and for antibody waning, we estimate a

71 otein vaccines and assessed the induction of antibody responses and a putative protective signature.

72 mutant mice developed robust donor-specific antibody responses and accelerated heart graft rejection

73 /MF59 vaccination elicited poor neutralizing antibody responses and an immunodominant response agains

74 elicited strong serum anti-CfaE and anti-LTB antibody responses and conferred significant reduction o

75 ve models to assess the correlations between antibody responses and demographic and clinical characte

76 In this study we evaluated the antibody responses and efficacy of an aluminum hydroxide

77 and their vaccine efficacy (antigen-specific antibody responses and IFN-gamma production) and biodist

78 Mumps virus-specific immunoglobulin G (IgG) antibody responses and mumps virus-neutralizing antibody

79 'resisters' possess IgM, class-switched IgG antibody responses and non-IFN-gamma T cell responses to

80 ke protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-indu

81 mal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complet

82 test novel gB vaccines to improve functional antibody responses and reduce AD-3 immunodominance.

83 ed for vaccine shedding, reactogenicity, RSV-antibody responses and RSV-associated medically attended

84 aim of the present study was to investigate antibody responses and safety of a third dose of measles

85 nt feature that both protects the virus from antibody responses and serves as a target for some highl

86 eted DNase DNASE1L3 develop rapid anti-dsDNA antibody responses and SLE-like disease.

87 we detect robust and sustained neutralizing antibody responses and the antibodies elicited by nucleo

88 Both monkeys responded with an anti-RRV antibody response, and quantitation of RRV DNA in periph

89 HIV-1 Env ligands; (iii) evasion of the host antibody response; and (iv) potential implications for t

90 Binding- and neutralizing-antibody responses appeared to be similar to those previ

91 Th1 and antibody responses are associated with prolonged recurre

92 ity and suboptimal virus-specific T cell and antibody responses are believed to cause severe disease

93 g rare B cells capable of broadly protective antibody responses are not hindered by promotion of term

94 oordinated CD4(+) T cell, CD8(+) T cell, and antibody responses are protective, but uncoordinated res

95 the most immunogenic vaccine candidates for antibody responses are recombinant proteins, which were

96 ne responses may contribute to protection if antibody responses are suboptimal.

97 derived for vp1, a capsid protein subject to antibody responses, are compared with those of analogous

98 induction of functionally active polyclonal antibody responses as measured in the standard membrane

99 reporting GAS emm-type or emm-type-specific antibody responses associated with rheumatic fever were

100 symptomatic cases since most patients had an antibody response at about 10 days after onset of sympto

101 st foreseen TIV-specific CD8+GRZ+ T-cell and antibody responses at D21.

102 uvanted qNIV induced post-vaccination wt-HAI antibody responses at Day 28 that were: statistically hi

103 primary endpoints were Env-specific binding antibody responses at weeks 28, 52, and 72 and safety an

104 ibody responses and mumps virus-neutralizing antibody responses (based on the focus-reduction neutral

105 vity mainly in tumored animals, with a lower antibody response being seen in nontumored animals, incl

106 viral strains can generate partially similar antibody responses, but these do not drastically differ

107 ntly and substantially increased anti-trimer antibody responses, but titer differences waned after tw

108 N38(HA1) glycan thus is pivotal in directing antibody responses by controlling access to group-determ

109 These eight antibody responses can serve as a biomarker, identifying

110 " viruses significantly enhances the anti-NA antibody response compared to vaccination with unmodifie

111 hemagglutinin (HA)-specific plasmablast and antibody responses compared to the nonadjuvanted vaccine

112 Neutralising antibody responses correlated strongly with antibody lev

113 cently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlle

114 ol of diverse pathogens requires an adaptive antibody response, dependent on cellular division of lab

115 Antibody responses develop following SARS-CoV-2 infectio

116 ed acute respiratory illness (RSV-MAARI) and antibody responses during the following RSV season.

117 and are a major contributor to neutralizing antibody responses elicited by infection.

118 Here, we analyze antibody responses elicited by the egg-adapted 3c3.A H3N

119 onal antibodies from an infected child whose antibody response focuses on the plateau epitope near th

120 The contribution of T cell and antibody responses following vaccination in resistance t

121 entile) responders based on vaccine-specific antibody responses following vaccination were further an

122 es rely on the essential contribution of the antibody responses for their protection.

123 nd peritoneal B-1 B cell development, the TI antibody response, fur pigmentation, and intestinal home

124 sufficient for immune escape from the broad antibody response generated in a natural host, as is a c

125 Tfh), CD4 lymphocytes critical for efficient antibody responses, have been shown to be key human immu

126 nd long-term (up to 1 year post-vaccination) antibody responses (hemagglutination inhibition, influen

127 luding DeltagD-2, that elicit polyfunctional antibody responses.IMPORTANCE Herpes simplex virus 1 is

128 ancing the magnitude and quality of anti-Env antibody responses.IMPORTANCE The results of the RV144 t

129 dding, and developed a strong virus-specific antibody response; importantly, they were protected when

130 ntly identified and shown to elicit a strong antibody response in COVID-19 patients.

131 ELISA)-based serological assays to study the antibody response in COVID-19 patients.

132 hern Hemisphere influenza vaccine elicits an antibody response in ferrets that is highly focused on a

133 nal characteristics and the relevance of its antibody response in human malaria have not been examine

134 also be informed by an understanding of the antibody response in infected patients.

135 onclude that there is no reduction of rabies antibody response in subjects taking Malarone or doxycyc

136 lectron microscopy and measured the maternal antibody response in the blood to this infection.RESULTS

137 GWAS reveals associations with KSHV antibody response in the HLA-B/C region (p = 6.64 x 10(-

138 arrhea in animals and elicits a neutralizing antibody response in virus-infected animals.

139 We examined antibody responses in 113 COVID-19 patients and found th

140 ies done in The Gambia, Mali, and Senegal of antibody responses in 193 children aged 12-23 months and

141 e, SARS-CoV-2-specific serology and salivary antibody responses in a family of two parents with PCR-c

142 In addition to neutralizing IgG antibody responses in a protective range, multifunctiona

143 ic CD4(+) and CD8(+) T cell and neutralizing antibody responses in acute and convalescent subjects.

144 en the changing dynamics of BVD virus (BVDV) antibody responses in cattle, classifying herds based on

145 Here, we show distinct antibody responses in children and adults after SARS-CoV

146 ic explanation for the limited durability of antibody responses in coronavirus infections, and sugges

147 s that allow the detection of viral specific antibody responses in COVID-19 patients or recovered ind

148 Here we measured the HIV-1-specific antibody responses in female New Zealand White rabbits a

149 ntified the induction of functional anti-CSP antibody responses in healthy malaria-naive adults (N=45

150 In this study we compared the antibody responses in humans after vaccination with an A

151 in balancing protective versus autoreactive antibody responses in humans are incompletely understood

152 influenza vaccine can substantially increase antibody responses in humans by effectively recruiting p

153 We compared antibody responses in humans vaccinated with Fluzone (eg

154 We compared antibody responses in humans vaccinated with Fluzone (eg

155 re both important for eliciting optimal H3N2 antibody responses in humans.

156 Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced inciden

157 CTLA-4 blockade augments HIV-1 Env antibody responses in macaques, and in a bnAb-precursor

158 GD3 vaccine plus beta-glucan elicited robust antibody responses in patients with HR-NB with prior PD.

159 moderate-to-low haemagglutination-inhibition antibody responses in people living with HIV.

160 ompatibility complex restriction, and absent antibody responses in recipients previously infected wit

161 l help mteaserrlie the diminished or altered antibody responses in repeatedly vaccinated subjects.

162 ivity, and functionality of NS1-specific IgG antibody responses in sera from a phase 2 clinical trial

163 dy titers, as well as Fc-mediated functional antibody responses, including antibody-dependent neutrop

164 Binding-antibody responses increased rapidly after the first imm

165 The modification of T-cell and antibody responses induced by TRAM was assessed in vivo

166 ssis immunization during pregnancy on infant antibody responses induced by whole-cell pertussis (wP)

167 IgE antibody responses initiated by these variant transcript

168 ts demonstrate that an individual's HA stalk antibody response is dependent on the specific subtype o

169 e show that the kinetics of the neutralizing antibody response is typical of an acute viral infection

170 f how different vaccine types elicit durable antibody responses is lacking.

171 Subjects in cluster 1 generally had lower antibody response magnitudes, except for antibodies targ

172 cts in clusters 2 and 3 typically had higher antibody response magnitudes, with the Fv specificity of

173 durable immunity, and primed for anamnestic antibody responses, making it an attractive candidate fo

174 nity mature these types of IgG C1C2-specific antibody responses may be one method by which to make an

175 s a specific statistical challenge: observed antibody responses measured in serological assays depend

176 oped unusually broad and potent neutralizing antibody responses, might serve as blueprints for HIV-1

177 le severe COVID-19 patients develop a strong antibody response, mild SARS-CoV-2 infections induce a m

178 trace mutation selection pathways where the antibody response must resolve cross-reactivity between

179 Pathogen-specific antibody responses need to be tightly regulated to gener

180 V-2-neutralizing antibodies, we analyzed the antibody response of 12 COVID-19 patients from 8 to 69 d

181 To this end, we analyzed the antibody response of 235 wild koalas, sampled longitudin

182 be broadly useful to quantify the functional antibody response of patients recovered from COVID-19 or

183 describe the kinetics of viral load and the antibody responses of 23 individuals with COVID-19 exper

184 Antibody responses of the volunteers, NHPs, and mice to

185 incorporate the effects of morphine-altered antibody responses on HIV/SIV dynamics.

186 nges in BAL cellular profiles (P = 0.02) and antibody responses (P = 0.01) at incremental doses befor

187 Of the measured antibody responses, positivity for IgG against the SARS-

188 uence the human immunodeficiency virus (HIV) antibody response produced during natural infection, lea

189 f the JCI, Secchi and collaborators describe antibody response profiles in 509 patients with COVID-19

190 We show that these allo-antibody responses reflect diminished Qa-1-restricted CD

191 g-Pf-exposed adults from Gabon, with similar antibody responses regardless of formulation.

192 y is often weak and mechanisms of triggering antibody responses remain poorly understood.

193 S-CoV-2 infection, the determinants of these antibody responses remain unclear.

194 Antibody responses remained increased (GMT >5000) in gro

195 In vaccinology, the induction of precise antibody responses remains a cornerstone for next-genera

196 eizures (RR: 1.25, 95% C.I. 1.08-1.46), mild antibody response (RR: 1.14; 95% C.I. 1.002-1.27), incre

197 on may exist along a spectrum and absence of antibody response should not be exclusionary in determin

198 Serum IgG and neutralizing antibody responses specific for all 4 glycoproteins were

199 a therapeutic vaccine inducing an effective antibody response still remains elusive.

200 Besides waning of antibody responses, suboptimal induction of T-cell respo

201 A booster dose of vaccine induced stronger antibody responses than a dose-sparing half-dose boost,

202 patients, males produce stronger SARS-CoV-2 antibody responses than females.

203 We review the antibody response that is triggered by severe acute resp

204 ry infection generates a robust neutralizing antibody response that mediates viral control and protec

205 tion correlated with induction of polyclonal antibody response that neutralized not only alpha-hemoly

206 nt that cats developed a robust neutralizing antibody response that prevented reinfection following a

207 hogens or their antigens triggers anamnestic antibody responses that are higher in magnitude and affi

208 However, antibody responses that correlate with recovery from RSV

209 MF59 elicited antibody responses that stimulated robust neutrophil pha

210 flu vaccines elicit strong antigen-specific antibody responses, they fail to provide effective, long

211 cently described a naturally occurring human antibody response to a parasite antigen that initiates a

212 proguanil (Malarone), and doxycycline on the antibody response to a purified chick embryo cell vaccin

213 By relating individual variations in antibody response to coronavirus disease 2019 (COVID-19)

214 The nature and longevity of the antibody response to coronaviruses are relevant to the p

215 The durably protective antibody response to DENV after primary infection is ser

216 y EBOV237 may play a role in the early human antibody response to EVD and should be considered in rat

217 Interestingly, the antibody response to H5 HA stem region was much lower af

218 To examine the human antibody response to HBV, we screened 124 vaccinated and

219 s identify a protein epitope targeted by the antibody response to KD and provide a means to elucidate

220 erological measures of transmission based on antibody response to S. mansoni soluble egg antigen (SEA

221 % of humans and 50% of dogs displayed a weak antibody response to saliva after the end of the sand fl

222 This study examines the duration of antibody response to SARS-CoV-2 in health care personnel

223 The nature and longevity of the antibody response to SARS-CoV-2 infection are not well d

224 However, little is known about the human antibody response to SARS-CoV-2(1-5).

225 compromised patients generally had a delayed antibody response to SARS-CoV-2, compared with immunocom

226 We review aspects of the antibody response to SARS-CoV-2, the causative agent of

227 ith severe disease (n = 38) develop a robust antibody response to severe acute respiratory syndrome c

228 laboratories in the characterization of the antibody response to the parasite have led to the identi

229 ustness, functionality, and longevity of the antibody response to the virus remain unanswered.

230 Antibody responses to 2,4,6-trinitrophenyl-conjugated ke

231 We measured IgG antibody responses to 342 P. vivax proteins in longitudi

232 n vaccinated with LAIV had serum and mucosal antibody responses to A/H3N2 and B, but only a mucosal I

233 nfection with different EEHVs and evaluating antibody responses to anti-EEHV vaccines.

234 ood transcriptional signatures predictive of antibody responses to both influenza and yellow fever va

235 w that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mu

236 Neutralizing antibody responses to coronaviruses mainly target the re

237 sed on A/New Caledonia/20/99 (H1N1) broadens antibody responses to cross-react with group 2 HAs.

238 Thailand, Brazil and the Solomon Islands and antibody responses to eight P. vivax proteins classified

239 influenza A/H3N2 using cross-sectional serum antibody responses to four strains in children aged 24-6

240 results in the development of Th1, Th17, and antibody responses to FRalpha in the majority of patient

241 ciated germinal centres can support targeted antibody responses to gut infections and immunization(1)

242 We analyzed antibody responses to H1 hemagglutinin stalk domain (H1/

243 We investigated antibody responses to hepatitis C virus (HCV) antigens E

244 M.tb infection is associated with increased antibody responses to heterologous pathogens in human su

245 ed unobserved infection times and underlying antibody responses to influenza A/H3N2 using cross-secti

246 In subjects receiving 3 mg/kg iscalimab, antibody responses to keyhole limpet hemocyanin were tra

247 bed the magnitude and breadth of circulating antibody responses to linear variable loop 2 (V2) and co

248 We measured the antibody responses to LJM17, LJM11, and DSG1 in normal s

249 To assess the strain-specificity of antibody responses to malaria infection and AMA1 vaccina

250 association between infant PFAS exposure and antibody responses to measles vaccination as well as mor

251 mut4 infection elicited IgG and neutralizing antibody responses to PEDV.

252 B-cell and antibody responses to Plasmodium spp., the parasite that

253 ger and broader SARS-CoV-2 responses, weaker antibody responses to prior infections, and higher incid

254 ly adjuvants plasma cell differentiation and antibody responses to protein antigens.

255 ale: Individuals with asthma have heightened antibody responses to rhinoviruses (RVs), although those

256 Antibody responses to SARS-CoV-2 are unimodally distribu

257 Antibody responses to SARS-CoV-2 can be detected in most

258 We charted longitudinal antibody responses to SARS-CoV-2 in 92 subjects after sy

259 However, there are reports that antibody responses to several malaria antigens in young

260 Molecular understanding of neutralizing antibody responses to severe acute respiratory syndrome

261 Human antibody responses to severe acute respiratory syndrome

262 convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in

263 Precise targeting of stem-directed antibody responses to the site of vulnerability by glyca

264 A way to increase the strength of antibody responses to these proteins is to present them

265 t precise analysis of the specificity of the antibody responses to this extremely complex fungal poly

266 n specificity, and functions associated with antibody responses to this pathogen have been elusive fo

267 We compared antibody responses to vaccination with recombinant E1E2

268 ermore, the immunogens refocused preexisting antibody responses toward defined neutralization epitope

269 Our aim was to evaluate systemic and mucosal antibody responses toward SARS-CoV-2 in mild versus seve

270 on is associated with complex and polyclonal antibody responses, typically composed of multiple antib

271 ENV2 E-based subunits has a strong impact on antibody responses, underscoring the importance of mimic

272 onnaire yearly, we report a high, persisting antibody response up to 9 years after vaccination for va

273 Some studies also described secondary antibody responses upon exposure.

274 ROAUC from the average of three antibodies' responses was 0.90; 95% CI 0.87-0.93, 90% se

275 A stronger antibody response was associated with disease severity.

276 , a substantial fraction of the neutralizing antibody response was mediated by public clones that rec

277 previously unrealized decline in preexisting antibody responses was observed.

278 agnitude and functionality of the anti-HIV-1 antibody response, we will have the foundation necessary

279 To assess the impact of vaccine type on antibody responses, we measured IgG isotypes against fou

280 a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoir

281 esins and their ability to induce intraclass antibody responses, we produced 28 antiadhesin monoclona

282 Normal VZV-specific T-cell immunity and antibody response were detected.

283 Systemic and local antibody responses were analysed by hemagglutination inh

284 Antibody responses were compared in adjusted analysis.

285 Neutralizing antibody responses were detectable in 36% by day 14 and

286 After the first vaccination, antibody responses were higher with higher dose (day 29

287 Longitudinal antibody responses were identified for neutralizing anti

288 Haemagglutination-inhibition antibody responses were measured for all groups in the m

289 IgA, IgM, and IgG and neutralizing antibody responses were quantified in serum of all indiv

290 Antibody responses were seen in a subset of patients.CON

291 IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS.

292 n (postvaccination) between H1/stalk and HAI antibody responses, whereas a strong correlation was obs

293 PIZV elicited a dose-dependent neutralizing antibody response which is protective for at least 1 yea

294 rsors, account for the majority of secondary antibody responses, while most primary-derived clonal di

295 e human population, it is not known how long antibody responses will be maintained or whether they wi

296 ce of prior SARS-CoV-2 exposure, mounting an antibody response with intact neutralization capability.

297 Env vaccine immunogens capable of eliciting antibody responses with greater neutralization breadth.

298 accinees showed robust B. pertussis-specific antibody responses with regard to significant increase i

299 the mature B-1 B cell repertoire and ensuing antibody responses, with implications for vaccination ap

300 D4(+) and CD8(+) T cell responses and strong antibody responses, with RBD-binding IgG concentrations